News

Modern Veterinary Therapeutics, LLC is proud to announce the FDA-approval of DETOMIDINE HYDROCHLORIDE (ANADA 200-674), the first FDA-approved generic detomidine hydrochloride injection (10mg/mL) for sedation & analgesia in horses. This product follows last year’s launches of MEDETOMIDINE HYDROCHLORIDE (ANADA 200-610), the first FDA-approved generic medetomidine hydrochloride injection (1mg/mL) and REVERTIDINE (ANADA 200-624), the first FDA-approved generic atipamezole hydrochloride injection (5mg/mL) for reversal of medetomidine and dexmedetomidine. We are excited to have now launched three of our most successful Canadian products into the U.S. Market. These FDA registrations showcase the regulatory expertise of our young company and our strong commitment to expand our presence in the US market. Refer to the FDA-CVM update: https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-detomidine-hydrochloride-injectable-solution-horses

June 13, 2019 – Modern Veterinary Therapeutics, LLC announces today that the Veterinary Drugs Directorate (VDD) has approved Dexvetidine^TM (dexmedetomidine injection – 0.5mg/mL) in Canada. Dexvetidine^TM, presented in a 10mL vial, is indicated for use as a sedative and analgesic in dogs and cats to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures. Dexvetidine^TM is also indicated for use as a preanesthetic to general anesthesia in dogs and cats. “Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada which further expands our veterinary line of sedative and analgesic products,” said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.

May 6, 2019 – Modern Veterinary Therapeutics, LLC announces today that the Australian Pesticides and Veterinary Medicines Authority (APVMA) has approved Ketoprofen V (ketoprofen injection – 100mg/mL) in Australia. Ketoprofen V is a nonsteroidal anti-inflammatory agent possessing anti-inflammatory, analgesic, and antipyretic properties approved for use in horses, swine, and cattle. The product is presented in 100ml and 250ml vials. “As we continue our aggressive global expansion strategy, Modern Veterinary Therapeutics is very excited to be adding to our pharmaceutical product line offered in the Australian market.” Said Dr. Cuong Tu Ba, Founder and President of Modern Veterinary Therapeutics, LLC.

February 6, 2019 – Modern Veterinary Therapeutics, LLC announces the U.S. launch of REVERTIDINE, the first FDA-approved generic atipamezole hydrochloride injection (5 mg/mL) for the reversal of dexmedetomidine and medetomidine in dogs. We are excited to bring one of our most successful Canadian products into the U.S. market and help our American veterinarians save more money.

November 12, 2016 – Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved Cloprostenol Veyx SW^TM (cloprostenol injection – 175μg/2mL) in Canada. Cloprostenol Veyx SW^TM, approved for use in swine, is presented in a 50mL vial. Cloprostenol Veyx SW^TM is a synthetic prostaglandin that induces farrowing in sows and gilts. Parturition and piglet viability are normal when Cloprostenol Veyx SW^TM is administered as early as 1 or 2 days before the expected farrowing date. “Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada demonstrating our commitment to expanding our reproductive production animal product line” said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.

Miami, FL January 6, 2016 — Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved Nerfasin 100^TM (xylazine injection – 100mg/mL) in Canada. Nerfasin 100^TM, presented in a 50mL vial, is indicated for use in horses when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. “Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada which further expands our veterinary line of sedative and analgesic products,” said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.

Miami, FL October 28, 2015 — Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved Nerfasin 20^TM (xylazine injection – 20mg/mL) in Canada. Nerfasin 20^TM, presented in a 25mL vial, is indicated for use in dogs, cats, and cattle when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. “Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada which further expands our veterinary line of sedative and analgesic products,” said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.

Miami, FL October 1, 2015  — Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved Ketoprofen V^TM (ketoprofen injection – 100mg/mL) in Canada. Ketoprofen V^TM, presented in 100mL and 250mL vials, is anonsteroidal anti-inflammatory agent possessing anti-inflammatory, analgesic, and antipyretic properties. Ketoprofen V^TM is approved for use in horses, swine, and cattle. Ketoprofen is the only NSAID approved in Canada with NO milk withdrawal period.  “Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada which further expands our line of products for the production animal industry, providing incredible savings to Canadian veterinarians and producers alike” said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.

Miami, FL July 31, 2014 — Modern Veterinary Therapeutics, LLC announces that the USDA-Center for Veterinary Biologics has approved our Canine Parvovirus-Coronavirus Antigen Test Kit. This new Canine Parvovirus-Coronavirus Antigen Test Kit is the first rapid in-clinic chromatographic immunoassay test in the U.S. market for the qualitative detection of both Coronavirus and Parvovirus antigens in canine feces simultaneously. Canine Parvovirus and Coronavirus cause sporadic outbreaks of vomiting and diarrhea in dogs. The rate of simultaneous infection of CPV and CCV is up to 25% of CPV infections (Evermann 1989,) and simultaneous infection is much more severe and fatal than a single infection. The clinical sign of CCV is usually mild enteritis, and some deaths have been reported in young dogs. The clinical signs of CPV and CCV are very similar (diarrhea and vomiting) making it difficult to differentiate which virus is the causative agent by clinical signs alone. The Canine Parvovirus-Coronavirus Antigen Test Kit is highly sensitive and specific, providing a positive or negative result in 5 minutes to help practitioners recognize these viruses in the clinic. The tests are easy to use, can be stored at room temperature, and have a 2-year shelf life.

Miami, FL June 15, 2014 — Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved  HYMATIL^TM (tilmicosin injection – 300 mg/mL) in Canada. HYMATIL^TM, presented in a 100mL multidose vial, is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia (Pasteurella) haemolytica and Pasteurella multocida and for the reduction of morbidity associated
with bovine respiratory disease (BRD) in feedlot calves, caused by Mannheimia (Pasteurella) haemolytica and Pasteurella multocida, during the first 30 days in the
feedlot, when administered at the time of arrival. HYMATIL^TMis indicated for the treatment of pneumonic pasteurellosis in lambs associated with Mannheimia (Pasteurella) haemolytica. “Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada demonstrating our commitment to further expanding our bovine product line including entrance into the beef cattle industry as well,” said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.